SCHEMBL1876357

SCHEMBL1876357

NCCCCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ ALDH1A1 P00352 3/20 1.00
▸ THRB P10828 2/20 1.00
▸ MEN1 O00255 2/20 1.00
▸ ALOX15 P16050 2/20 1.00
▸ PLG P00747 1/20 1.00
▸ SLC6A2 P23975 1/20 1.00
▸ RECQL P46063 1/20 1.00
▸ SLC6A3 Q01959 1/20 1.00
▸ NFKB1 P19838 2/20 0.94
▸ CYP2D6 P10635 1/20 0.94
▸ BLM P54132 2/20 0.89
▸ NPSR1 Q6W5P4 2/20 0.89
▸ TSHR P16473 6/20 0.78
▸ HDAC11 Q96DB2 6/20 0.78
▸ GABRR3 A8MPY1 1/20 0.78
▸ GABRP O00591 1/20 0.78
▸ GABRD O14764 1/20 0.78
▸ HDAC3 O15379 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
12-Aminododecanoic Acid SCHEMBL1235115 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
Adipic Acid SCHEMBL258770 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
SCHEMBL2230318 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
SCHEMBL332272 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
SCHEMBL472263 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
Sebacic Acid SCHEMBL5378952 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
Aminocaproic Acid SCHEMBL21141584 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
12-Aminododecanoic Acid SCHEMBL20767098 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
Pimelic Acid SCHEMBL21465298 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1
SCHEMBL188819 1.00 LMNA (1.00) LMNAKMT2AALDH1A1THRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889878-B1 BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS MERCK FROSST CANADA INC (CA) 2002-09-04 — — EP claimed
US-4085130-A MOLECULAR SIEVES AND ALKALINE EARTH SILICATES AS CATALYSTS PHILLIPS PETROLEUM COMPANY (US) 1978-04-18 — — US claimed
CN-114763369-A Aliphatic peptide chain and Fab-aliphatic chain conjugate 正大天晴药业集团股份有限公司 2022-07-19 — — CN disclosed
EP-3842178-A1 BRAZING MATERIAL, BRAZING MEMBER, HEAT EXCHANGER, AND MANUFACTURING METHOD OF BRAZING MEMBER Harima Chemicals, Incorporated (JP) 2021-06-30 — — EP disclosed
CN-113056524-A Coloring composition 住友化学株式会社 2021-06-29 — — CN disclosed
US-20210187672-A1 BRAZING MATERIAL, BRAZING MEMBER, HEAT EXCHANGER, AND PRODUCING METHOD OF BRAZING MEMBER HARIMA CHEMICALS, INCORPORATED (JP) 2021-06-24 — — US disclosed
CN-112996860-A Coloring composition 住友化学株式会社 2021-06-18 — — CN disclosed
US-9463262-B2 Cell adhesive material for biological tissue SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-11 — — US disclosed
US-20130289254-A1 CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-31 — — US disclosed
EP-2636415-A1 CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE Sanyo Chemical Industries, Ltd. (JP) 2013-09-11 — — EP disclosed
US-20110105417-A1 Drug Conjugates THE CURATORS OF THE UNIVERSITY OF MISSOURI 2011-05-05 — — US disclosed
US-5360914-A Intermediates for superoxide dismutase derivatives KURARAY CO., LTD. (JP) 1994-11-01 — — US disclosed
US-5352689-A Rhizoxin derivatives and their use as anti-tumor agents SANKYO COMPANY, LIMITED (JP) 1994-10-04 — — US disclosed
US-5238837-A Antiinflammatory agents, antiulcer agents KURARAY CO., LTD. (JP) 1993-08-24 — — US disclosed
EP-0350315-B1 RHIZOXIN DERIVATES AND THEIR USE AS ANTI-TUMOR AGENTS SANKYO COMPANY LIMITED (JP) 1993-06-16 — — EP disclosed
EP-0507348-A2 Superoxide dismutase derivatives KURARAY CO., LTD. (JP) 1992-10-07 — — EP disclosed
EP-0350315-A1 Rhizoxin derivates and their use as anti-tumor agents SANKYO COMPANY LIMITED (JP) 1990-01-10 — — EP disclosed
US-4085130-A MOLECULAR SIEVES AND ALKALINE EARTH SILICATES AS CATALYSTS PHILLIPS PETROLEUM COMPANY (US) 1978-04-18 — — US disclosed
US-4069277-A ZINC DIHYDROCARBYL DITHIOPHOSPHINATE PHILLIPS FIBERS CORPORATION (US) 1978-01-17 — — US disclosed
US-4059653-A ZINC ALKYL SULFINATE PHILLIPS PETROLEUM COMPANY (US) 1977-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105417-A1 Drug Conjugates ABCB1, SLCO2B1, ABCG2 LMNA 2282/4885KMT2A 3940/4885ALDH1A1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback